Announcement on Appointment of Officers

Cellusion Inc. (Head Office: Tokyo; CEO: Shin Hatou; hereinafter referred to as “Cellusion”), which has “Regenerating Human Potential” as its mission and aims to meet the demands of corneal transplant patients worldwide with its unique technique that efficiently produces corneal endothelial substitute cell from iPS cells, is pleased to announce that Norihisa Kobayashi and Hiromi Furushima have been newly appointed as outside corporate auditors.
Under the new management structure, Cellusion will further accelerate its R&D toward the social implementation of corneal regenerative medicine, including the development of cell therapy using iPS cell-derived corneal endothelial substitute cell (hereinafter referred to as “CLS001”) aiming for the treatment of bullous keratopathy, which is our lead program.

Outside Corporate Auditor　 Norihisa Kobayashi (newly appointed)
Outside Corporate Auditor　 Hiromi Furushima (newly appointed)
Outside Corporate Auditor　 Hiroshi Ishiai (resigned)

[About Norihisa Kobayashi]
After graduating from Fukushima University’s Faculty of Economics, Mr. Kobayashi worked for Hokkaido Takushoku Bank, Ltd. and then engaged in underwriting at Daiwa Securities Co. Ltd. He has been involved in the listing of approximately 50 companies and has a track record of working with a total of 300 companies. In the public underwriting business, he was involved in activities to strengthen cooperation with IPO-related parties such as venture capital firms, auditing firms, and printing companies, as well as in support activities for companies preparing for listing.
As a representative of Daiwa Securities, he also served as a member of the Japan Securities Dealers Association and the Tokyo Stock Exchange’s rule revision committee. He then became the first full-time auditor (outside) at Japan Management Succession Support Co. Ltd.
He has been active in establishing rules and procedures for auditing and establishing internal management systems, focusing on governance and internal control, in preparation for the IPO.

[About Hiromi Furushima]
After graduating from the University of Tokyo Faculty of Law, Ms. Furushima studied at Stanford Law School and was admitted to the Japanese bar and the California State Bar.
She gained experience in corporate legal affairs at law firms including Nishimura & Partners (currently Nishimura & Asahi), and later served as in-house counsel at Novartis, gained experience in legal, intellectual property, and compliance matters in pharmaceutical industry. She also served as a Corporate Officer of Novartis Pharma K.K.
Ms. Furushima is currently a Director, International Legal at Alnylam Japan K.K. and an Outside Director of PRISM BioLab Co.,Ltd. where she contributes to solving management issues and ensuring sound and proper corporate management.

[About Cellusion]
Cellusion is a regenerative medicine startup originating from the Department of Ophthalmology, Keio University School of Medicine, with “Regenerating Human Potential” as its mission and “More Freedom and More Smiles to the World” as its vision. Based on patented technology such as its proprietary technique of efficiently producing corneal endothelial substitute cell from iPS cells, Cellusion is promoting R&D aimed at meeting medical needs from the perspective of “patient centricity” by leveraging cutting-edge regenerative medicine technology, including the lead program CLS001 that aims to meet the global corneal transplant demands.

Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: 8-6 Nihonbashi-Kobuna, Chuo, Tokyo 103-0024, JAPAN
Founded: January 2015
URL: https://cellusion.jp/en/

For further information: please ask us through the contact form on our website.